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Abstract
The aim of this study was to investigate the efficacy and suitability of a brief integrative intervention, Personalized Integrative
Therapy (PI Therapy), for the treatment of adult depression and/or anxiety. In this 6-week, 3-arm, parallel-group, randomized
trial, PI Therapy delivered alone or with nutritional supplements (PI Therapy þ Supps) was compared to cognitive behavior
therapy (CBT) in 48 adults with depression and/or anxiety. All treatments were delivered as a 1-day workshop plus 6 weeks of
reminder phone text messages to reinforce topics and skills covered in the workshop. Affective symptoms decreased significantly
and to the same extent in all 3 conditions. At the end of treatment, 33% to 58% of participants reported levels of depressive
symptoms in the normal range, and 50% to 58% reported nonclinical levels of anxiety. Compared to CBT and PI Therapy, PI
Therapy þ Supps was associated with significantly greater improvements in sleep quality. These findings suggest that a brief
integrative intervention with or without supplements was comparable to CBT in reducing affective symptoms in adults with
depression and/or anxiety. However, sleep quality improved only in the PI Therapyþ Supps condition. These findings will require
replication with a larger cohort.
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The most common treatments for adult depression and anxiety
comprise psychological therapy and pharmaceutical antide-
pressants. Psychological therapies target change in unhelpful
thoughts and coping skills, with a review of meta-analyses
indicating cognitive behavioral therapy (CBT) is the “gold
standard” psychological treatment for affective disorders.1,2
Pharmaceutical antidepressants are believed to target neuro-
transmitters such as serotonin and noradrenaline, with the most
popular antidepressant classes comprising selective-serotonin
reuptake inhibitors and selective-noradrenaline reuptake inhi-
bitors.3 However, while these treatments are effective, there
remains a significant portion of individuals who experience
either no or only partial response. In a meta-analysis of 34
studies and 2500 participants, a response rate (defined as
50% reduction in depression scores from baseline) of 49%
(95% confidence interval 42% to 56%) was reported following
an average of 10 sessions of CBT.4 An average remission rate
of 45% (95% confidence interval 39% to 51%) from CBT was
also reported in this meta-analysis. In a comparison of CBT
with second-generation antidepressants, outcome rates were
found to be similar with response rates of 44% and 45%, and
remission rates of 41% and 48%, respectively.5
In addition to their moderate rates of efficacy, CBT and
antidepressant medications are associated with several treat-
ment barriers and/or adverse effects. CBT requires sound intel-
lectual competence, insight into personal affective and
cognitive processes, a willingness to disclose personal infor-
mation, transportation to attend sessions, and time and
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willingness to attend regular sessions ranging from 10 to 20
sessions.6,7 Pharmaceutical antidepressants are associated with
several adverse effects including nausea, weight gain, fatigue,
headache, sedation, and sexual dysfunction.8 Adverse effects
are cited as common reasons for treatment refusal and early
discontinuation.9,10 Developing new interventions and/or
delivery formats that overcome some of these barriers to suc-
cessful treatment are, therefore, important to increase treatment
efficacy and accessibility.
Depression and anxiety are influenced by many factors
including psychological, biological, lifestyle, and dietary fac-
tors.11 For example, associations between diet,12 physical activ-
ity,13 sleep,14 and social relationships15 have been confirmed in
depression and anxiety. Targeting these factors for intervention
may, therefore, boost treatment efficacy. Indeed, in a recently
published psychiatry commission, the need for developing hol-
istic interventions for people with a mental disorder, including
treatments that optimize physical and mental health was high-
lighted.16 As an adjunct to pharmacotherapy, exercise,17 diet-
ary,18 and nutraceutical/herbal interventions such as saffron,
folate, vitamin D, and omega-3 polyunsaturated fatty acids19-
21 are associated with greater treatment efficacy. However, there
has been limited investigation into the efficacy of an integrative
intervention that targets a combination of individually chosen
psychological, dietary, lifestyle, medical, social, and spiritual
factors. Based on the available limited evidence, positive results
from a 12-week open-label study consisting of several lifestyle
interventions (eg, diet, exercise, and mindfulness)22 and an 8-
week mindfulness-based program with elements of nutrition and
exercise23 for the treatment of depression and anxiety were
identified. However, in a 12-week randomized controlled trial
there were no differences in mental health outcomes in adults
with depression and/or anxiety treated with a lifestyle interven-
tion comprising dietary, exercise, and other lifestyle changes
compared to an attention control with scheduled telephone con-
tact.24 Moreover, a 12-week lifestyle program provided to
patients with a mental illness (major depressive disorder or
bipolar disorder) and comorbid metabolic syndrome was asso-
ciated with no significant changes in mental health measures,
although there was a significant reduction in body mass index
and abdominal circumference.25
Even though CBT is often delivered via regular attendance at
face-to-face individual or group therapy sessions, other formats
of delivery are available and have some evidence to support their
efficacy. These include internet delivery, telephone counselling,
or through smartphone applications.26-28 There is also evidence
that CBT delivered as a 1-day workshop can effectively reduce
depressive symptoms and improve mood in adults with depres-
sion with gains maintained for up to 2 years.29-31
The aim of this study was to assess the efficacy and feasibility
of Personalized Integrative Therapy (PI Therapy), an integrative
intervention for adults with depression and anxiety, including
any additive benefits of dietary supplements. Treatment was
delivered as a 1-day workshop plus 6 weeks of regular follow-
up phone text messaging. The efficacy of PI Therapy (with or
without supplements) was compared to CBT to examine changes
in affective symptoms, sleep quality, overall life quality, diet,
and exercise habits. Due to increasing positive findings associ-
ated with nutraceutical and herbal supplementation on depres-
sive and anxiety symptoms, a PI Therapy plus supplements arm
was included in this study to examine whether the addition of
supplements to an integrative intervention could enhance treat-
ment outcomes. In several meta-analyses, it has been confirmed
that supplementation with saffron,32 curcumin,33 probiotics,34
and omega-3 fatty acids35 are associated with reduced depres-
sive and/or anxiety symptoms. However, most studies have been
stand-alone interventions and the efficacy of supplementation as
a component of a comprehensive integrative intervention has
received little attention in the scientific literature. Moreover,
in nutraceutical and herbal clinical trials, the efficacy of single
supplements is most commonly examined. However, consumers
may take several supplements at a time. By better emulating
real-world behaviors associated with supplementation, we
examined the acceptability and tolerability of a treatment com-
prising multiple supplements. Because depression and anxiety
are associated with multiple physiological disturbances (ie, neu-
rotransmitter disturbances, hypothalamic-pituitary-adrenal axis
dysregulation, mild chronic inflammation, and increased oxida-
tive stress)36 herbs and nutraceuticals targeting these various
mechanisms were also chosen. It was hypothesized that PI Ther-
apy would be at least comparable to CBT in improving mood,
anxiety, and relevant behaviors that can influence mental and
physical well-being. Moreover, the addition of supplements was
hypothesized to increase treatment outcomes associated with
mood and sleep quality.
Materials and Methods
Study Design
A 6-week, 3-arm, parallel-group, randomized trial, with a 6-week
follow-up, was undertaken (Figure 1). Participants were informed that
the goal of the study was to compare the efficacy of a lifestyle-based
treatment with a validated standard treatment for depression and/or
anxiety, and that they would be allocated randomly into 1 of 3 groups.
Participants became aware of treatment allocation on attendance of the
1-day workshop; however, they were not aware of the content covered
in the other workshops. Study investigators were aware of treatment
group allocation. However, this is unlikely to have introduced bias as
all outcome measures were completed online by participants.
In this trial, the sample size was influenced by resource availability
and was therefore likely underpowered. However, as the goal of this
trial was to investigate the efficacy and feasibility of PI Therapy,
delivered via a brief intervention, it still enabled the formation of
preliminary conclusions and will help establish future directions for
research in more adequately powered studies.
Recruitment and Randomization
Participants were recruited across Perth, Western Australia, through
social media advertisements between May and June 2019. Interested
participants were directed to a website landing page providing details
about the study and a link to complete an initial online screening
questionnaire. This online questionnaire screened for current
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depressive and/or anxiety symptoms, medication use, suicidal idea-
tion, self-harm behaviors, history of medical/psychiatric disorders,
alcohol, nicotine, and other drug use, supplement and vitamin intake,
and pregnancy/breastfeeding status. If assessed as likely eligible,
volunteers participated in a phone interview with an investigator. The
phone interview comprised a structured series of questions examining
the eligibility criteria specified below.
Eligible and consenting participants completed baseline assess-
ments and were randomly assigned to 1 of 3 groups (PI Therapy, PI
Therapy þ Supps, or CBT) using a randomization calculator (http://
www.randomization.com). The randomization calculator ensured
sequence concealment. The randomization structure comprised 5 ran-
domly permuted blocks, containing 10 participants per block. The
participant identification number was allocated according to the order
of participant enrolment in the study. Participants were informed of a
date to attend a workshop but were not informed of treatment alloca-
tion until the day of attendance.
Participants
Inclusion Criteria. Male and female participants aged 18 to 65 years
with self-reported mild to moderately severe depression and/or anxi-
ety as assessed by the DASS-21 were recruited for this trial (ie, DASS-
21 depression score from 10 to 28 and/or anxiety score from 8 to 22).
If participants were taking psychotropic medication, they were
required to be taking a stable dose for at least 8 weeks. Participants
were also required to be fluent in English and to have consented (via
an electronic consent form) to all pertinent aspects of the trial.
Exclusion criteria. Participants with a reported DSM-5 (Diagnostic and
Statistical Manual of Mental Disorders, Fifth Edition) diagnosis of
bipolar disorder, schizophrenia, psycho-organic syndromes, eating
disorders, substance abuse, or dependence disorders were ineligible
to participate in the study. Participants who were engaging in self-
harm behaviors and/or reported serious suicidal ideation were also
Figure 1. Systematic illustration of study design.
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excluded from the study. Participants with a major medical illness
affecting their ability to implement many of the lifestyle, dietary, and
psychological changes covered in the program were also excluded.
Medical disorders included but were not limited to cancers, serious
cardiovascular disease, neurodegenerative disorders (eg, Alzheimer’s
disease, multiple sclerosis, and Parkinson’s disease), and unmanaged
metabolic disorders such as diabetes. Participants currently receiving
psychological therapy for depression or anxiety by a mental health
practitioner or who had a known allergy or significant intolerance to
natural supplements were also ineligible to participate in the study.
Interventions
All participants attended a 1-day workshop (PI Therapy, PI Therapyþ
Supps, or CBT). Each workshop was held on a weekend and lasted
approximately 6 hours. The content of each workshop is provided in
Supplementary Table 1. Participants were provided with 3 handouts
consisting of (1) copies of slides, (2) checklists and questionnaires that
were completed during the workshop, and (3) goal-setting and moni-
toring sheets that participants were asked to complete for 6 weeks.
Throughout the workshop, attendees were required to evaluate their
skills/behavior in specified areas by completing relevant questionnaires
or reflection sheets, each of which was tailored to content delivered in
respective workshops. The goal was for attendees to identify factors
that may be contributing to his/her depression and/or anxiety and to
establish potential future goals for change. The goal-setting and mon-
itoring workbook was completed at the end of the workshop. Specifi-
cally, participants were asked to set 3 to 5 goals for the forthcoming
week based on the content covered in the workshop. Throughout the
week, participants were asked to record whether they achieved their
goal on the monitoring chart provided. At the completion of each week,
participants were asked to review their goals and set new ones. New
goals could include setting the same goal again, making the goal easier
or more difficult based on their previous week’s performance, and/or
setting a completely new goal based on other areas covered in the
workshop. The goal-setting and monitoring booklet was held by parti-
cipants and copies were not given to investigators.
After the workshops, all participants were sent phone text mes-
sages every 2 to 3 days reminding them of content covered in the
workshop, encouraging them to continue to work on their goals, or
reminding them to complete weekly rating forms or relevant outcome
measures. The texts sent to PI Therapy and PI Therapy þ Supps
groups were identical apart from one text which was sent to the PI
Therapy þ Supps group, which reminded participants about their
supplement intake. In total, each participant received approximately
25 text messages during the first 6 weeks. No messages were sent after
week 6 apart from reminders to complete questionnaires at weeks 9
and 12.
Three group facilitators attended all workshops, although one facil-
itator (AL) presented the material and coordinated group exercises
during all workshops. This facilitator is a clinical psychologist with
22 years of clinical experience, significant training and experience in
CBT, and the founder of PI Therapy.
All participants in the PI Therapy þ Supps condition were pro-
vided with several supplements at the end of the workshop. These
supplements were unbranded, listing only the ingredients and direc-
tions for use. All supplements were provided by Metagenics (Aust)
Pty Ltd and produced in an Australian-approved, Good Manufacturing
Practice facility. The supplements included the following:
1. Fish oil (2 capsules daily, taken at one time or in divided doses).
Each capsule delivered 500 mg of eicosapentaenoic acid and 200
mg of docosahexaenoic acid.
2. B-complex (1 tablet taken in the morning). Each tablet delivered
450 mg of ascorbic acid (vitamin C), 300 mg calcium pantothe-
nate (vitamin B5), 50 mg citrus bioflavonoids extract, 50 mg
thiamine hydrochloride (vitamin B1), 50 mg nicotinamide (vita-
min B3), 50 mg pyridoxal 5-phosphate monohydrate (vitamin B6),
20 mg riboflavin sodium phosphate (vitamin B2), 500 mg Biotin,
200 mg levomefolic acid (5-methyltetrahydrofolate), 200 mg
mecobalamin (co-methylcobalamin; vitamin B12).
3. Probiotic (1 capsule daily taken at any convenient time). Each
capsule delivered total live organisms—25 billion colonizing
forming units (CFUs) comprising 11.5 billion CFUs Lacto-
bacillus acidophilus (NCFM), 11.5 billion CFUs Bifidobacterium
lactis (Bi-07), and 2 billion CFUs Lactobacillus rhamnosus
(LGG).
4. Magnesium powder formula (1 serve taken in water in the eve-
ning). Each serve delivered 350 mg of magnesium as magnesium
bisglycinate, 3 g of taurine, 2 g of glutamine, 362 mg of potassium
as potassium citrate, 500 mg of vitamin C as calcium ascorbate
dihydrate, 25 mg of thiamine hydrochloride (vitamin B1), 25 mg
of riboflavin (vitamin B2), 25 mg of nicotinamide (vitamin B3), 25
mg of pyridoxal 5-phosphate monohydrate (vitamin B6), and 10
mg of zinc as amino acid chelate (zinc bisglycinate).
5. Saffron and curcumin (1 capsule, twice daily). Each capsule
delivered 15 mg of a saffron extract (affron) and 500 mg of a
curcumin extract (BCM-95).
Outcome Measures
All outcome measures (except weekly task ratings) were completed at
baseline (1 to 7 days prior to workshop attendance) and 3, 6, 9, and 12
weeks after the workshop. All measures were completed via self-
directed online surveys.
Primary outcome measures
Depression, Anxiety, and Stress Scale–21 (DASS-21). The DASS-
21 is a validated self-report measure assessing symptoms of stress,
anxiety, and depression.37 Twenty-one questions are rated on a 4-point
scale (0-3), ranging from never to almost always (lower scores indi-
cate a reduction in symptoms).
Secondary Outcome Measures
Pittsburgh Sleep Quality Index (PSQI). The PSQI is a reliable and
valid 19-item self-report questionnaire that assesses sleep quality over
the previous month.38,39 Scores are calculated to derive 7-component
scores comprising sleep duration, sleep disturbance, sleep latency,
sleep efficiency, daytime dysfunction, subjective sleep quality, use
of sleeping medication, and overall global sleep quality.
Short Form-36 Health Survey (SF-36). The SF-36 is a self-report
measure assessing the quality of life. It consists of 8 scaled scores
measuring (1) vitality, (2) physical functioning, (3) bodily pain, (4)
general health perceptions, (5) physical role functioning, (6) emo-
tional role functioning, (7) social role functioning, and (8) mental
health. The SF-36 is a commonly used outcome measure of quality
of life with strong psychometric properties.40,41 Scoring for the SF-36
was based on the algorithm developed by RAND Health Care.42
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Perseverative Thinking Questionnaire (PTQ). The PTQ is a
15-item measure of repetitive, intrusive negative thinking that people
find difficult to disengage from. Repetitive thoughts are also defined
as unproductive and capture significant mental capacity. The PTQ is a
reliable and valid measure that correlates positively with depressive
symptoms as measured by the Beck Depression Inventory and the
Inventory of Depressive Symptomatology.43
Mediterranean Diet Adherence Questionnaire (MDAQ). The
MDAQ is a 14-item questionnaire designed to assess adherence to a
Table 1. Baseline Demographic Details of Participants.
PI Therapy
(n ¼ 15)
PI Therapy þ Supps
(n ¼ 14) CBT (n ¼ 19) P value
Age, mean (SE) 39.8 (2.98) 40.07 (3.47) 39.32 (2.95) .985a
BMI 30.29 (1.77) 30.01 (1.55) 29.22 (1.77) .884a
Gender Female 67% 86% 84% .354a
Marital status Single 27% 14% 42% .392b
Married 40% 29% 37%
Divorced 20% 29% 5%
De facto 13% 29% 16%
Educational level Secondary 47% 57% 58% .933b
Tertiary 33% 21% 21%
Postgraduate 20% 21% 21%
Antidepressant use Yes 60% 43% 37% .390b
Mental health type Depression 13% 7% 5% .941b
Anxiety 27% 29% 32%
Combined 60% 64% 63%
Duration of depression/anxiety 6 to 12 months 13% 0% 5% .060b
1 to 2 years 13% 7% 0%
2 to 5 years 0% 0% 16%
5 to 10 years 0% 36% 16%
10þ years 73% 57% 63%
Last time depression/anxiety free 1 to 2 years 27% 7% 0% .032b
2 to 5 years 0% 29% 21%
5 to 10 years 7% 29% 32%
10þ years 67% 36% 47%
DASS-21 scores Depression 16.67 (2.11) 20.29 (2.29) 20.63 (2.27) .400a
Anxiety 11.33 (1.83) 14.29 (2.55) 13.89 (2.14) .605a
Stress 21.47 (1.79) 23.71 (2.06) 21.05 (1.72) .569a
Total 49.47 (4.23) 58.29 (5.06) 55.58 (5.07) .461a
PSQI Duration 1.07 (0.28) 1.00 (0.28) 1.26 (0.25) .764a
Disturbance 1.40 (0.16) 1.5 (0.17) 1.58 (0.14) .713a
Latency 1.2 0.30) 1.79 (0.30) 1.58 (0.27) .383a
Dysfunction 1.47 (0.17) 1.86 (0.10) 1.74 (0.13) .144a
Efficiency 0.93 (0.34) 1.14 (0.29) 1.37 (0.27) .579a
Subjective sleep quality 1.47 (0.24) 1.64 (0.17) 1.63 .769a
Medications 1.00 (0.35) 0.57 (0.27) 0.53 (0.22) .430a
Global Score 8.53 (1.11) 9.50 (0.97) 9.68 (1.02) .708a
SF-36 Physical functioning 85.67 (4.57) 90.71 (3.95) 82.89 (3.83) .410a
Role limitations due to physical health 75.00 (9.76) 71.43 (10.10) 72.37 (9.91) .969a
Role limitations due to emotional problems 31.07 (9.48) 30.79 (7.39) 24.58 (6.69) .790a
Energy/fatigue 34.33 (5.04) 29.64 (4.46) 24.47 (3.22) .239a
Emotional well-being 50.13 (2.64) 46.00 (3.50) 45.05 (3.55) .525a
Social functioning 56.93 (5.45) 51.14 (4.02) 52.16 (5.67) .727a
Pain 67.93 (3.01) 61.21 (6.00) 67.84 (5.70) .682a
General health 56.33 (5.47) 55.71 (5.74) 49.47 (4.42) .559a
Perseverative Thinking Qu 36.93 (1.97) 37.57 (2.37) 37.42 (2.29) .980a
Mediterranean Diet Qu 15.93 (0.91) 17.00 (1.13) 17.11 (1.04) .685a
IPAQ Vigorous activity (MET minutes/week) 357.33 (145.04) 1204.57 (533.57) 484.21 (305.61) .221a
Moderate activity (MET minutes/week) 318.67 (155.20) 791.43 (311.92) 287.37 (115.14) .151a
Walking (MET minutes/week) 829.55 (147.37) 1716.68 (455.65) 1057.74 (251.88) .127a
Category low 13% 21% 26% .255b
Category medium 60% 36% 63%
Category high 27% 42% 11%
Abbreviations: PI Therapy, Personalized Integrative Therapy; CBT, cognitive behavior therapy; SE, standard error; BMI, body mass index; DASS-21, Depression,
Anxiety, and Stress Scale–21; PSQI, Pittsburgh Sleep Quality Index; SF-36, Short Form-36 Health Survey; IPAQ, International Physical Activity Questionnaire.
aOne-way ANOVA.
bPearson w2 test.
Lopresti et al 5
Mediterranean diet. The MDAQ is validated against the more com-
prehensive and validated Food Frequency Questionnaire that is com-
monly used in epidemiological studies.44,45
International Physical Activity Questionnaire, Short Form (IPAQ).
The IPAQ is a 7-item self-report measure assessing physical activity
patterns over the last 7 days. Metabolic equivalent of task scores
(METS) for vigorous activity, moderate activity, and walking is cal-
culated. The IPAQ has sound psychometric properties.46
Process Measures
Weekly task ratings. To assess attitudes toward treatments, from
weeks 1 to 6 participants rated primary topics covered in each work-
shop. Participants were required to rate on a 5-point scale how impor-
tant a task was for the week, how much effort was allocated to the task,
and how much success was achieved. In the 2 PI Therapy groups,
participants rated the following: improve my diet, take my supple-
ments (PI Therapy þ Supps group only), improve my sleep, increase
my physical activity, improve my psychology and coping skills,
improve my social connections, increase my life purpose and mean-
ing, and improve medical and physical conditions that might be affect-
ing my mental health. In the CBT group, participated rated the
following: identify my triggers, identify my thoughts, change my
thoughts, accept my thoughts, increase my activity, learn a relaxation
skill, and increase exposure to situations I avoid.
Supplement intake. To monitor supplement intake, at week 6 par-
ticipants in the PI Therapy þ Supps group recorded the number of
tablets or powder they had remaining.
Adverse events. Tolerability of supplement intake by participants
in the PI Therapy þ Supps group was assessed at week 6 through an
online question querying adverse effects that were believed to be
associated with supplement intake. Participants were also requested
to contact researchers immediately if any adverse effects were
experienced.
Treatment fidelity. To monitor adherence to the content and tasks
planned for each 1-day workshop, one cofacilitator in attendance of all
workshops completed a checklist at the end of the workshop. This
checklist was designed to monitor adherence to the content covered
in each workshop by the primary workshop facilitator.
Statistical Analysis
A 1-way ANOVA was used to compare demographic variables across
the 3 treatment groups for continuous variables, and Pearson’s w2 was
used to compare categorical data. Total and subscale scores (where
relevant) on the DASS-21, PSQI, SF-36, PTQ, MDAQ, and IPAQ
were analyzed for time (baseline and mean score across weeks 3, 6,
9, and 12) and group (PI Therapy versus PI Therapy þ Supps; PI
Therapy conditions combined vs CBT) using a repeated-measures
analysis of variance (ANOVA). Scores were averaged across weeks
3 to 12 as preliminary analyses indicated that treatment effects were
present from week 3 onwards and did not change appreciably through-
out follow-up (Supplementary Tables 2-5). To examine the clinical
relevance of treatment effects, the percentage change from baseline
was calculated. Eta-squared was calculated to examine effects sizes.
The percentage of participants with depression or anxiety subscale
scores in the normal range on the DASS-21 was also calculated and
a Pearson’s w2 analysis was conducted to compare between-group
differences. This was conducted after excluding participants who
scored in the normal range at baseline. As an exploratory analysis,
for participants allocated to the PI Therapy conditions, Spearman’s r
correlations between change in DASS-21 total score (from baseline to
mean of weeks 3 to 12) and weekly ratings of effort, importance, and
success were conducted.
The Shapiro-Wilk normality test was conducted to examine the
normality of group data. This demonstrated that data were not nor-
mally distributed, and transformations were unable to normalize data.
However, a repeated-measures ANOVA was considered the most
appropriate option for statistical analyses as it is relatively robust to
violations of normality.47 Where necessary, degrees of freedom were
adjusted using the Greenhouse-Geisser approach to correct for viola-
tions of the sphericity assumption. Data from participants were
included in analyses if questionnaire data were obtained at week 3
(last observation carried forward [LOCF] from week 3 for missing




Baseline Questionnaire and Demographic Information. From 135
people completing the initial online screening questionnaire, 48
volunteers attended a 1-day workshop. A total of 87 individuals
were either ineligible or did not attend the 1-day workshop for
the following reasons: 28 people did not meet the eligibility
criteria, 20 people failed to attend the 1-day workshop despite
meeting the eligibility criteria and agreeing to participate in the
study, 14 people were unable to attend the 1-day workshop at
the allocated times, and 25 people did not respond to contact by
the investigator or did not complete the initial questionnaires.
Data from 44 participants were used for statistical analyses
and 40 participants completed all questionnaires over the 12-
week period. Six participants withdrew or did not complete
questionnaires during the 6-week intervention and 2 people
withdrew during the follow-up period (ie, weeks 6 to 12). There
were no significant differences in dropout rates across groups.
Reasons for withdrawal included failure to complete question-
naires with no reason given (n¼ 6), illness of a family member
(n ¼ 1), and hospitalization for an unrelated medical illness (n
¼ 1). No participants withdrew from the study due to reported
adverse events associated with supplement intake.
Outcome Measures
DASS-21 (Primary Outcome Measure)
Changes in DASS-21 total and subscale scores across the 3
treatment groups and repeated-measures ANOVA significance
levels are detailed in Table 2 and Figure 2. All treatments were
associated with statistically significant reductions in DASS-21
total and subscale scores. Mean percentage improvements from
baseline ranged from 22% (DASS-21 stress score in the CBT
group) to 41% (DASS-21 depression score in the PI Therapy þ
Supps group). A 38%, 59.7%, and 26.8% variance from base-
line, as measured by Z2, was observed in the DASS-21 total
score in the PI Therapy, PI Therapy þ Supps, and CBT con-
ditions, respectively. As detailed in Table 2, between-group




















































































































































































































































































































































































































































































































































































































































































































































































































































































analyses on all DASS-21 scores revealed nonsignificant time
group interactions in PI Therapy versus PI Therapy þ Supps
and PI Therapy combined versus CBT.
The percentage of participants scoring in the normal range
on the DASS-21 depression and anxiety subscale scores is
detailed in Figure 3. A Wilcoxon signed-rank test revealed
there were statistically significant increases in the number of
participants scoring in the normal range for depression in the PI
Therapy (P ¼ .025) and PI Therapy þ Supps (P ¼ .014) con-
ditions but not the CBT condition (P ¼ .102). A statistically
significant increase in the number of participants scoring in the
nonclinical range for anxiety occurred in the CBT condition (P
Figure 2. Change in DASS-21 scores (error bars depict standard error).
Figure 3. Percentage of participants in the normal range (DASS-21 scores).
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¼ .046), but not the PI Therapy (P ¼ .317) or PI Therapy þ
Supps condition (P ¼ .083). However, a Pearson’s w2 analysis
revealed no statistically significant between-group differences
between PI Therapy combined and CBT for depression, w(1) ¼
.621, P ¼ .431, or anxiety, w(1) ¼ .068, P ¼ .794. There were
also no statistically significant between-group differences
between PI Therapy and PI Therapy þ Supps for depression,
w(1) ¼ .851, P ¼ .356, or anxiety, w(1) ¼ .032, P ¼ .858.
SF-36 (Secondary Outcome Measure 1)
Changes in SF-36 subscale scores across the 3 treatment groups
and repeated-measures ANOVA significance levels are
detailed in Table 3. In the PI Therapy condition, statistically
significant treatment effects were observed in role limitations
due to physical health (F1,13 ¼ 4.72, P ¼ .049, Z2 ¼ 26.6%),
energy/fatigue (F1,13 ¼ 4.92, P ¼ .045, Z2 ¼ 27.5%), emo-
tional well-being (F1,13 ¼ 8.20, P ¼ .013, Z2 ¼ 38.7%), and
general health (F1,13 ¼ 4.92, P ¼ .045, Z2 ¼ 27.5%). In the PI
Therapy þ Supps condition, statistically significant treatment
effects were observed in role limitations due to emotional prob-
lems (F1,11 ¼ 5.05, P ¼ .046, Z2 ¼ 31.4%), energy/fatigue
(F1,11 ¼ 13.35, P ¼ .004, Z2 ¼ 54.8%), emotional well-being
(F1,11¼ 7.76, P¼ .018, Z2¼ 41.4%), pain (F1,11¼ 12.92, P¼
.004, Z2 ¼ 54%), and general health (F1,11 ¼ 12.53, P ¼ .005,
Z2 ¼ 53.3%). In the CBT condition, statistically significant
treatment effects were observed in role limitations due to emo-
tional problems (F1,17 ¼ 11.84, P ¼ .003, Z2 ¼ 41.1%), emo-
tional well-being (F1,17 ¼ 8.34, P ¼ .010, Z2 ¼ 32.9%), and
social functioning (F1,17 ¼ 3.06, P ¼ .022, Z2 ¼ 15.3%). As
detailed in Table 3, between-group analyses on all SF-36 scores
revealed nonsignificant time  group interactions in PI Ther-
apy versus PI Therapy þ Supps and PI Therapy combined
versus CBT. However, a near-significant interaction was
observed in pain scores between PI Therapy versus PI Therapy
þ Supps condition (F1,24 ¼ 4.029, P ¼ .056, Z2 ¼ 14.4%).
PSQI (Secondary Outcome Measure 2)
Changes in PSQI subscale scores across the 3 treatment groups
and repeated-measures ANOVA significance levels are
detailed in Table 4. As detailed in Table 4, between-group
analyses revealed significant time group interactions in sleep
latency for PI Therapy versus PI Therapy þ Supps (F1,24 ¼
5.30, P¼ .030, Z2¼ 18.1%) and PI Therapy combined vs CBT
(F1,42 ¼ 5.71, P ¼ .021, Z2 ¼ 12%). There were also statisti-
cally significant time group interactions in global sleep for PI
Therapy versus PI Therapyþ Supps (F1,24¼ 4.41, P¼ .046, Z2
¼ 15.5%) and PI Therapy combined versus CBT (F1,42 ¼ 5.22,
P ¼ .027, Z2 ¼ 11.1%). No statistically significant treatment
effects were observed in the CBT group on any subscale score.
In the PI Therapy condition, a statistically significant treatment
effect occurred in subjective sleep quality (F1,13 ¼ 4.79, P ¼
.047, Z2 ¼ 26.9%) and a near-significant effect in global sleep
quality (F1,13¼ 4.28, P¼ .059, Z2¼ 24.8%). In the PI Therapy
þ Supps condition statistically-significant treatment effects
were observed in sleep disturbance (F1,11 ¼ 9.43, P ¼ .011,
Z2 ¼ 46.2%), sleep latency (F1,11 ¼ 9.81, P ¼ .010, Z2 ¼
47.1%), sleep dysfunction (F1,11 ¼ 7.86, P ¼ .017, Z2 ¼
41.7%), subjective sleep quality (F1,11 ¼ 8.19, P ¼ .015, Z2
¼ 42.7%), and global sleep score (F1,11 ¼ 22.24, P ¼ .001, Z2
¼ 66.9%).
IPAQ (Secondary Outcome Measure 3)
Changes in IPAQ subscale scores across the 3 treatment groups
and repeated-measures ANOVA significance levels are
detailed in Table 5. There were no statistically-significant
increases in vigorous activity, moderate activity, or walking
in any treatment condition.
MDAQ (Secondary Outcome Measure 4)
Changes in MDAQ total score across the 3 treatment groups
and repeated-measures ANOVA significance levels are
detailed in Table 5. As detailed in Table 5, between-group
analyses revealed a significant time  group interaction
between PI Therapy combined versus CBT (F1,42 ¼ 16.13, P
< .001, Z2 ¼ 27.8%) but not between PI Therapy versus PI
Therapy þ Supps (F1,24 ¼ 0.042, P ¼ .840, Z2 ¼ 0.2%).
Statistically significant increases in MDAQ total score were
observed in the PI Therapy (F1,13 ¼ 21.08, P ¼ .001, Z2 ¼
61.8%) and PI Therapyþ Supps conditions (F1,11¼ 20.46, P¼
.001, Z2 ¼ 65%), but not the CBT group (F1,17 ¼ 1.45, P ¼
.245, Z2 ¼ 7.9%).
PTQ (Secondary Outcome Measure 5)
Changes in the PTQ total score across the 3 treatment groups
and repeated-measures significance levels are detailed in
Table 5. Statistically significant reductions in PTQ total scores
were observed in the PI Therapy (F1,13¼ 11.63, P¼ .005, Z2¼
47.2%), PI Therapy þ Supps (F1,11 ¼ 20.05, P ¼ .001, Z2 ¼
64.6%), and CBT conditions (F1,17 ¼ 10.20, P ¼ .005, Z2 ¼
37.5%). As detailed in Table 5, there were no significant time
 group interactions for PI Therapy versus PI Therapyþ Supps
and PI Therapy combined versus CBT.
Mean Weekly Ratings (Process Measure)
Mean weekly ratings (weeks 1 to 6) on the primary topics/skills
covered in each 1-day workshop are detailed in Supplementary
Table 6. Although statistical analyses were not undertaken due
to the small sample sizes, in the PI Therapy group, highest
importance, effort and success ratings were given for improv-
ing diet quality, followed by improving coping skills and sleep
quality. In the PI Therapy þ Supps group, the highest impor-
tance, success, and effort ratings were provided for taking sup-
plements, followed by improving coping skills and diet quality.
In the CBT group, the highest ratings were provided for chang-
ing thoughts, followed by identifying thoughts, increasing
activity, and learning relaxation skills.






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Spearman’s r correlations between mean ratings (from
weeks 1 to 6) in importance, effort, and success with a change
in the total DASS-21 score are detailed in Supplementary
Table 7 (for PI Therapy groups only). Higher ratings of impor-
tance (r¼ .482, P¼ .013) and effort (r¼ .394, P¼ .047) but not
success (r ¼ .239, P ¼ .240) in improving diet quality were
positively associated with improvements in the total DASS-21
score. Higher ratings in effort (r¼ .443, P¼ .023) and success (r
¼ .443, P¼ .027) in improving medical and physical conditions
that might affect mental health were positively associated with
improvements in total DASS-21 score. Higher success ratings (r
¼ .533, P ¼ .005) in changing psychological and copings skill
were associated with improvements in DASS-21 score.
Intake of Supplements
At week 6, participants in the PI Therapy þ Supps group
recorded their quantity of remaining supplements. All partici-
pants reported taking greater than 80% of their supplements
except one participant who only consumed 10% of her curcu-
min/saffron capsules but took greater than 80% of the remain-
ing supplements.
Adverse Events
No significant adverse events were reported by participants,
with similar dropout rates across the 2 conditions. No partici-
pants withdrew from the study due to concerns associated with
supplement intake.
Treatment Fidelity
The treatment fidelity checklist completed by a co-facilitator
confirmed that the primary workshop facilitator adhered to
content and exercises planned for each workshop, as outlined
in Supplementary Table 1.
Discussion
In this 6-week, randomized, 3-arm trial, an integrative treatment
for depression and/or anxiety (PI Therapy) with or without nutri-
tional supplements was found to be at least as effective as a
similarly delivered format of CBT. Treatment was provided as
a 1-day workshop followed by regular phone texts over a 6-week
period, reminding participants of topics covered in the workshop
and encouraging them to set weekly goals for change.
Affective symptoms, as measured by the DASS-21 total and
subscale scores, improved in all treatment groups and there were
no statistically significant differences among the treatment con-
ditions. However, this study was likely underpowered to detect
any but large between-group differences. In this population of
adults with mild-to-moderate severity of depression and/or anxi-
ety, 33% to 58% of participants reported levels of depressive
symptoms in the normal range at the end of treatment, and 50%
to 58% reported nonclinical levels of anxiety. Even though con-
firmation is required in a larger clinical trial with clearly defined
mental health populations and validated self-report and
clinician-administered outcome measures, these results are
comparable to those obtained from standard delivery CBT and
pharmaceutical interventions. For example, in a meta-analysis
of 34 studies, CBT delivered for an average of 10 sessions was
associated with a remission rate of 45% in adults with depres-
sion.3 An average remission rate of 48% was also identified in a
meta-analysis on second-generation antidepressants.4
Despite improvements in affective symptoms occurring in all
treatment conditions, improvements in sleep quality were
detected only in the PI Therapy þ Supps condition. Compared
to CBT and PI Therapy, PI Therapy þ Supps was associated
with significantly greater improvements in sleep latency and
global sleep quality, as measured by the PSQI. Overall, partici-
pants in the PI Therapy þ Supps condition reported improve-
ments in sleep disturbance, sleep latency, sleep dysfunction,
subjective sleep quality, and global sleep quality. PI Therapy
alone was associated with a statistically significant improve-
ment in subjective sleep quality and a near-significant improve-
ment in global sleep quality. However, there were no
statistically significant changes in sleep quality following par-
ticipation in CBT. These results suggest that supplementation
comprising magnesium, B-vitamins, omega-3 fish oil, probio-
tics, saffron, and curcumin may enhance sleep quality. As these
supplements were taken in combination it cannot be determined
if changes in sleep quality were due to one or a combination of
these ingredients. Moreover, as there was no placebo control, it
is feasible that the simple act of taking supplements may have
contributed to improvements in sleep quality. However, this is
unlikely given the large, clinically meaningful changes in sleep
quality. Supplementation with magnesium,48 saffron,49-51
omega-3-polyunsaturated fatty acids,52 and probiotics53 have
been associated with improvements in sleep quality. Even
though further research is required to understand how these
nutrients and plant extracts improve sleep quality, their sleep-
enhancing effects may be due to their influence on serotonergic,
hypothalamic-pituitary-adrenal axis activity, and anti-
inflammatory mechanisms. For example, omega-3 fatty acid
and magnesium supplementation is associated with reduced
inflammation and cortisol concentrations.54-56 Saffron and pro-
biotics have also been shown to lower inflammation and cortisol
concentrations and may influence serotonergic activity.55-59
Alterations in these physiological mechanisms have been iden-
tified in insomnia and other sleep disturbances.60-62 It is impor-
tant to note that treating poor sleep leads to improvements in
affective and anxious symptoms among people with mental dis-
orders and increases the effectiveness of evidence-based treat-
ments for depression and anxiety.63,64 As a result, sleep
improvements seen in the PI þ Supps group may moderate a
greater improvement in mental health symptoms, and this
requires investigation via a longer-term follow-up.
Improvements in quality of life, as measured by the SF-36,
and perseverative thinking were observed across all treatment
groups, with no statistically significant, between-group differ-
ences, apart from a near-significant greater improvement in pain
in the PI Therapy þ Supps group compared to PI Therapy.
Increases in diet quality as measured by the MDAQ were
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observed in the 2 PI Therapy conditions. A higher score on the
MDAQ indicates an increase in a Mediterranean dietary pattern
characterized by increased consumption of fruits, vegetables,
legumes, whole-grains, olive oil, and a reduced intake of pro-
cessed foods, sweets, and soft drinks. The importance of dietary
changes was not covered in the CBT workshop, and as expected,
no change in dietary patterns was reported by participants in the
CBT condition. No changes in physical activity, as measured by
the IPAQ was observed in any treatment condition.
While these treatment effects should be considered tentative
until confirmed in larger, adequately powered, and controlled
studies, the results are certainly encouraging. In this study, the
eligibility criteria were relatively broad to increase the likeli-
hood of recruiting a representative sample of mostly moderate-
to-severely depressed and/or anxious adults motivated to make
changes to improve their mental well-being. In fact, approxi-
mately 60% of participants reported experiencing depression
and/or anxiety for greater than 10 years and almost 50% were
currently taking a pharmaceutical antidepressant. Despite this,
approximately 40% to 60% of participants in the PI Therapy
conditions reported that levels of depression and/or anxiety had
decreased to within the normal range following treatment. Even
more encouraging is the efficient, cost-effective intervention
that was offered to participants which included attending a 1-
day workshop and automated SMS texts every 2 to 3 days to
remind participants of topics covered in the workshop and to
encourage them to set weekly goals for change. These improve-
ments were also maintained during a 6-week follow-up.
PI Therapy comprising personalized goal-setting targeting
diet, sleep, physical activity, psychological coping skills, life
purpose and meaning, social connections, and general physi-
cal/medical health was well received by participants. The pro-
cess of empowering people to choose a target for change, rather
than a clinician deciding what to change, might be an important
factor in facilitating change and increasing treatment acceptabil-
ity for participants.65 In a meta-analysis of 23 studies, it was
confirmed that when patients exercise control over their health
care decisions, there are improved treatment outcomes and an
approximate 50% reduced likelihood of treatment dropout.66 No
participants withdrew from the study due to the content covered
in the workshop. In fact, improving diet and taking supplements,
along with enhancing psychological coping skills were rated by
participants as the most important components of the interven-
tion, and the ones they reported exercising the greatest effort and
success in changing. The importance of diet in enhancing mental
health was further highlighted by an exploratory analysis of
weekly ratings by participants in the PI Therapy conditions
where higher ratings in importance and effort to change diet
quality were positively associated with greater improvements
in mood. However, no such associations were found in partici-
pants ratings associated with improving sleep, increasing phys-
ical activity, improving psychological coping skills, increasing
social connections, or increasing purpose and life meaning. This
suggests that attitudes and behaviors associated with improving
diet quality may be important components of change. This will
require further investigation in controlled experimental studies.
Emerging research suggests a protective effect of healthy diets
such as the Mediterranean diet on depression.67,68 The results
from 2 dietary interventions in depressed adults also indicate
that dietary changes can effectively lower depressive and anxi-
ety symptoms.18,69
In addition to diet, the results of this study indicate that in
participants receiving PI Therapy, the more effort and success
an individual reported in improving medical and physical con-
ditions, the greater the improvement in affective symptoms as
measured by the total DASS-21 score. This suggests that allo-
cating efforts at improving physical health can have a positive
effect on mental health. Self-rating of success (but not impor-
tance or effort) at improving psychological coping skills was
also positively associated with improved mental health. These
results require more comprehensive investigation in future
clinical trials, as understanding the most essential components
of an intervention can help improve treatment models.
Despite encouraging participants to increase physical activ-
ity, no significant increases in physical activity (eg, walking,
moderate, and vigorous activity) were found in any treatment
condition. Changes in physical activity were assessed with the
IPAQ, a self-report measure of physical activity. While this is a
validated instrument with sound psychometric properties, sig-
nificant variability in respondents’ estimates of activity was
noted by investigators. Seasonal changes in physical activity
may also have impacted on changes in activity as the work-
shops were conducted in autumn and follow-up assessments of
physical activity occurred in winter months.
Limitations and Directions for Future Research
In this study, encouraging effects of an integrative, brief inter-
vention (PI Therapy) to reduce depressive and anxiety symp-
toms in adults with depression and/or anxiety were identified.
However, these findings should be considered preliminary and
require confirmation in larger well-controlled trials. The lack
of a no-treatment control group precludes an analysis of the
extent of improvements associated with the passage of time or
placebo effects. This study was also underpowered, and based
on the effect sizes achieved in this study, it is anticipated that a
total sample size of approximately 160 would be required to
detect between-group differences in affective symptoms
between PI Therapy and CBT. Moreover, the therapeutic
effects of this integrative intervention delivered in different
formats should be investigated. All treatments were delivered
as a 1-day, 6-hour workshop, plus 6-weeks of SMS texts. Both
PI Therapy interventions were found to be at least comparable
to CBT. However, CBT is most often delivered as a weekly
group or individual intervention ranging from 10 to 20 ses-
sions. Examining the differing efficacy of PI Therapy delivered
as a weekly individual or group intervention ranging from 6 to
20 sessions will allow an analysis of the costs to benefits asso-
ciated with different treatment delivery formats. It will also
allow a comparison of PI Therapy to CBT when delivered in
its most-validated format.
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The addition of nutritional supplements (B-complex, mag-
nesium, curcumin, saffron, fish oil, and a probiotic) was well
tolerated by participants and may have enhanced treatment
efficacy. In particular, greater improvements in sleep quality,
physical function, and pain were reported by participants in the
PI Therapy þ Supps group. In the future, a placebo-controlled
comparison will be important to determine the robustness of
this finding.
It is important that PI Therapy is investigated in different
populations to determine its efficacy and feasibility. Advertis-
ing for this study occurred via social media where participants
were informed that the purpose of the study was to compare the
effects of a lifestyle-based intervention with a validated inter-
vention for depression and anxiety. While participants were not
provided with details about the treatments, it is possible that a
population interested in lifestyle and dietary interventions was
recruited. To evaluate the generalizability of study results, it is
therefore important that the efficacy of PI Therapy is evaluated
in participants with a range of demographic and psychographic
characteristics, and levels of readiness to make changes.
PI Therapy comprises several areas of intervention covering
the following domains: diet and nutrition, lifestyle and environ-
ment, psychology and coping skills, social and spiritual, and
medical and physical. Targeting change in several areas that can
influence mental well-being may be associated with greater
treatment efficacy. However, utilizing an intervention consist-
ing of multiple components prohibits analysis of the most effec-
tive components of an intervention. Whether improvements in
mental health were due to one or several components within PI
Therapy could not be determined. One remedy is to investigate
the efficacy of each intervention in isolation. However, this
approach opposes a primary assumption of an integrative inter-
vention where multiple, small changes can have large therapeu-
tic effects. This will require consideration in future studies.
Finally, investigators in this study were not blinded, which
may potentially impact on outcomes. However, outcome mea-
sures comprised online, self-report measures. Following the
1-day workshop, investigators had no personal contact with
participants. This limits the likelihood of investigator influence
on study outcomes. However, it may be prudent in future studies
for outcomes to be assessed by investigators blinded to treatment
conditions. In addition, objective outcome measures may be
helpful. This may include the collection of actigraphy and poly-
somnography data to assess changes in physical activity and
sleep patterns.
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